Ambrosia Space Manufacturing Corporation¶
Early-stage in-space biomanufacturing startup, ex-Intuitive Machines founder
Updated: Session 99 (2026-04-07)
Company Profile¶
| Field | Value |
|---|---|
| Location | Houston, TX |
| Type | Startup (unfunded as of 2025 Tracxn profile) |
| Founded | 2023 |
| CEO/Founder | Mario M. Maggio |
| Co-I on FO | Zara Nemati |
| Team | James Mahoney (joined by Jan 2026, per LinkedIn) |
| Employees | Small but growing — actively hiring across hardware engineering, bioprocess engineering, software, business dev, regulatory |
Mario Maggio is a former Intuitive Machines propulsion and AI&T engineer who participated in 50+ hotfire test operations and designed the propellant throttle valve for IM's lander. He holds an MS in Aerospace Engineering (Bioastronautics) from CU Boulder and a BS from University of Alabama. Haverford College alumnus (Class of 2013).
Vision: "In Space, you can make better drugs." The company positions biomanufacturing in microgravity as the core platform — crystallizing biologics to create uniform, injectable, and stable medications, plus production of drugs, fuels, nutrition, bioplastics.
FO Project¶
184146 — Cell Separation Centrifuge for Nutrient Production for Crewed Missions¶
- Status: Active (Jun 2025 – Jun 2027)
- TRL: Not yet reported
- TX: TX06.3.1 Medical Diagnosis and Prognosis
- Destination: Moon and Cislunar, Mars, Others Inside the Solar System
- Flight: Parabolic flights (microgravity environment)
- Technology: Cell-Sep — a centrifuge designed to process large volumes (>2L) of liquid-based cell culture from bioreactors in reduced/microgravity. Continuous operation, low power, low flow rate. No existing flight-proven cell separation system exists for space. Earth systems aren't designed for the operational constraints (low flow rate, low power, continuous).
Mission context: The first payload planned is ISS-bound — the ABBY mission (summer 2026 target) will deploy a 2.5L bioreactor + centrifuge in orbit. Detailed ABBY specs: - 2.5L bioreactor cell-culture volume - Full sensor suite with sparging and pH control - In-line centrifuge with 3 L/hr separation capability - Culture, supernatant, and biomass sampling - Compatible with both microbial and mammalian cells - Described as "an order-of-magnitude increase in on-orbit bioprocessing capability"
TechPort Footprint¶
| Project | Program | Role | Period | Notes |
|---|---|---|---|---|
| 184146 | FO | Lead | 2025–2027 | Cell-Sep centrifuge |
Single TechPort project. No prior SBIR/STTR history under Ambrosia Space.
Funding¶
USASpending ($179K, 1 award)¶
| Award | Amount | Agency | Period | Description |
|---|---|---|---|---|
| FA955025PB006 | $179.4K | DoD / Air Force | May–Oct 2025 | STTR Phase I — Co-cultures for beta-carotene production in microgravity |
Notable: The only USASpending award is Air Force, not NASA. The FO project is NASA-funded but through FO's TechLeap mechanism, not SBIR. The Air Force STTR Phase I focuses on beta-carotene (vitamin A precursor) production via microbial co-cultures — nutritional supplement for military/astronaut applications.
No NASA contracts found in USASpending.¶
No venture funding reported (Tracxn lists as "unfunded" as of 2025).¶
Upstream Lineage¶
- Founder trajectory: Intuitive Machines (propulsion/AI&T engineer) → CU Boulder MS (Bioastronautics) → founded Ambrosia Space (2023)
- Intuitive Machines connection: Maggio was hands-on with IM's lunar lander hardware — 50+ hotfire tests, throttle valve design, vehicle-level assembly. This gives credibility on space hardware development even though biomanufacturing is a different domain.
- No prior academic publications found in this space
Downstream Potential¶
- ISS deployment: ABBY mission (summer 2026 target) — the near-term milestone. If successful, this would be the largest bioreactor system ever flown to space.
- BIO International Convention 2026: Ambrosia is exhibiting at BIO 2026, the world's largest biotech conference. This signals they're actively seeking biopharma partnerships and investors — not just a space company talking to space people. This is where Varda and other in-space manufacturing companies have also recruited pharma partners.
- Factories in Space: Listed on Factories in Space directory alongside established players (Redwire, Varda, Space Tango)
- Dual-track: The Air Force STTR (beta-carotene co-cultures) suggests military nutritional applications alongside NASA crew nutrition
- Long-term vision: Scalable biomanufacturing for drugs, fuels, nutrition, bioplastics in space — ambitious for a pre-revenue startup, but the BIO Convention presence suggests they're building the commercial relationships to support it
Assessment¶
| Dimension | Rating |
|---|---|
| Technology readiness | Very early (no prior flight heritage; FO = first microgravity test) |
| Funding trajectory | Minimal — $179K total government funding |
| Team | Credible founder (IM hardware experience) but thin team |
| Downstream impact | Too early to assess |
| Confidence | Speculative — true early-stage, no demonstrated product |
Time dimension: Founded 2023, first government award 2025, FO project 2025–2027. At most 2 years old as an operating company. This is the earliest-stage entity in the current FO cohort.
Key insight: Ambrosia Space is a bet on the in-space biomanufacturing market that Redwire, Varda, and others are developing. The FO Cell-Sep project tests a specific subsystem (cell separation from bioreactor output) that's necessary for production-scale operations. Maggio's IM background provides space hardware credibility, but the biomanufacturing domain expertise is less clear. The Air Force STTR on beta-carotene co-cultures is the most interesting signal — it suggests dual-use nutritional applications that could provide an early revenue path.
What changed (Session 61): ABBY mission specs now detailed (3 L/hr centrifuge, full sensor suite, microbial + mammalian cell compatible). BIO International Convention 2026 exhibitor — first sign of biopharma outreach. James Mahoney joined team. Active hiring across 5 disciplines. Assessment unchanged (still speculative/early-stage) but activity level is increasing.
Session 99 Refresh (2026-04-07)¶
No material change since Session 61. USASpending unchanged ($179K, 1 Air Force STTR). No new contracts found. Air Force STTR Phase I (FA955025PB006) ended Oct 2025 — no Phase II visible in USASpending, which is a negative signal. BIO 2026 exhibitor status confirmed. Tracxn still lists as "unfunded." ABBY ISS mission target of "summer 2026" is imminent — no public updates on timeline or National Lab allocation.
Assessment update: The lack of Phase II STTR and continued "unfunded" status after 3 years of operation increases risk. The ABBY mission is the make-or-break milestone — if it doesn't fly in 2026, Ambrosia's viability becomes questionable given thin funding.
Open Questions¶
- What's the ISS ABBY mission timeline — is National Lab time secured? (Website says "summer 2026" — due NOW)
- Does Maggio have biomanufacturing collaborators/advisors with domain expertise? (Hiring for bioprocess engineering suggests gap being filled)
- Is there venture interest, or is this purely grant-funded? (BIO Convention presence suggests active fundraising)
- How does Cell-Sep compare to existing ISS centrifuges (e.g., KUBIK)?
- ~~What happened with the Air Force STTR Phase I (ended Oct 2025) — any Phase II?~~ → No Phase II found in USASpending (negative signal)
Sources: TechPort 184146; USASpending; Ambrosia Space website; Balerion Space Ventures webinar; Tracxn; Factories in Space; BIO International Convention 2026 exhibitor listing